Calton & Associates Inc. purchased a new stake in Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 865 shares of the medical instruments supplier’s stock, valued at approximately $203,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Legacy Advisors LLC grew its position in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 490 shares during the last quarter. FTB Advisors Inc. grew its position in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 290 shares during the last quarter. Harfst & Associates Inc. grew its position in shares of Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd grew its position in Becton Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 338 shares in the last quarter. Finally, Exane Derivatives grew its position in Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 628 shares in the last quarter. 75.56% of the stock is currently owned by hedge funds and other institutional investors.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by company insiders.
A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target for the company in a report on Friday, January 19th. Bank of America reissued a “buy” rating and issued a $260.00 price target on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Citigroup raised shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $237.27.
Becton Dickinson and Co (NYSE BDX) traded up $0.36 on Friday, hitting $222.87. The stock had a trading volume of 960,058 shares, compared to its average volume of 1,682,278. Becton Dickinson and Co has a 12 month low of $175.66 and a 12 month high of $248.39. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $59,337.36, a PE ratio of 170.13, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. Becton Dickinson and’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business earned $2.33 earnings per share. equities research analysts anticipate that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.35%. Becton Dickinson and’s payout ratio is presently 229.01%.
ILLEGAL ACTIVITY NOTICE: “865 Shares in Becton Dickinson and Co (BDX) Acquired by Calton & Associates Inc.” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/18/calton-associates-inc-purchases-new-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.